The Efficacy of Adalimumab in Children with Chronic Non-infectious Posterior Uveitis and Panuveitis: A Retrospective Cohort Study

作者全名："Tao, Tianyu; Yang, Shizhao; He, Daquan; Peng, Xuening; Wang, Zhenyu; Jiang, Qi; Wang, Tianfu; Su, Wenru"

作者地址："[Tao, Tianyu; Yang, Shizhao; He, Daquan; Peng, Xuening; Wang, Zhenyu; Jiang, Qi; Wang, Tianfu; Su, Wenru] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangdong Prov Key Lab Ophthalmol & Visual Sci, 54 Xianlie S Rd, Guangzhou 510000, Peoples R China; [Yang, Shizhao] Chongqing Med Univ, Dept Ophthalmol, Affiliated Hosp 2, Chongqing, Peoples R China; [Su, Wenru] Guangdong Prov Clin Res Ctr Ocular Dis, 54 Xianlie S Rd, Guangzhou 510000, Peoples R China"

通信作者："Su, WR (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangdong Prov Key Lab Ophthalmol & Visual Sci, 54 Xianlie S Rd, Guangzhou 510000, Peoples R China.; Su, WR (通讯作者)，Guangdong Prov Clin Res Ctr Ocular Dis, 54 Xianlie S Rd, Guangzhou 510000, Peoples R China."

来源：OPHTHALMOLOGY AND THERAPY

ESI学科分类：　

WOS号：WOS:001187297300001

JCR分区：Q2

影响因子：2.6

年份：2024

卷号：　

期号：　

开始页：　

结束页：　

文献类型：Article; Early Access

关键词：Adalimumab; Biologics; Intraocular inflammation; Pediatric uveitis; Treatment

摘要："Introduction This study aimed to assess the efficacy and safety of adalimumab in pediatric patients with chronic non-infectious posterior uveitis and panuveitis (not associated with juvenile idiopathic arthritis). Methods The medical records of children (< 18 years old) with chronic non-infectious posterior uveitis and panuveitis were collected and analyzed in this retrospective cohort study. Children were allocated to a conventional adalimumab-free treatment (CT) or adalimumab (ADA) group based on whether they additionally received adalimumab. Results In total, 69 children (138 eyes) were included, with 21 (42 eyes) and 48 (96 eyes) in the CT and ADA groups, respectively. During the average follow-up period of 24 months, the improvement in all ocular parameters (best-corrected visual acuity, intraocular inflammation, fluorescein angiography score) was better in the ADA group than in the CT group, except for changes in central macular thickness, which did not significantly differ between the groups. The mean time of first alleviation, which was after 1.03 +/- 0.12 months of therapy, was earlier in the ADA group than in the CT group (2.30 +/- 0.46 months). In the ADA group, 90.6% of children had remission within 3 months, and 47.9% had no relapse during follow-up. Cough and cold were the most common adverse events in the ADA group; however, the number of adverse events was similar between both the groups. Conclusions Adalimumab was effective in the treatment of chronic noninfectious posterior uveitis and panuveitis in pediatric patients, and disease inactivity was accomplished in the majority of the patients, thereby improving visual outcomes and maintaining disease stability. Adverse events were limited and tolerable."

基金机构：National Outstanding Youth Science Fund Project of National Natural Science Foundation of China

基金资助正文：We extend our heartfelt gratitude to all the participants and their parents who generously dedicated their time and effort to contribute to this research.